New data suggest the potential of a significant impact of using biomarkers to reduce the need for biopsies and personalize transplant patient care. Non-invasive testing using gene-based blood or urine could offer transplant patients personalized care and medication and may replace the need for costly, invasive biopsy procedures that can be risky for patients.